- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03447132
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant (SAFIA)
Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®
This is a multicenter, international, double-blind randomized Phase III study to evaluate the pathological complete response (pCR) according to Chevalier classification between Fulvestrant® and the combination of Fulvestrant® plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer.
Eligible patients will be assessed upfront using the OncotypeDX® molecular test (Recurrence Score <31).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, international, double-blind, randomized study.
Eligible patients based on inclusion/exclusion criteria will be assessed using OncotypeDX molecular test. Patients with low/intermediate risk (Recurrence Score <31) will be treated with the induction neoadjuvant Fulvestrant (500 mg (milligram) intra muscular(i.m) at Day 1, 14 and 28 and then every 4 weeks), plus Goserelin (3.6 mg subcutaneous (s.c) every 4 weeks, only for pre and peri-menopausal patients) for 4 months, followed by clinical and radiological assessment of the disease response.
Patients with objective response or stabilization will be randomized and treated for 4 additional months with:
- Fulvestrant 500 mg i.m every 4 weeks (+ Goserelin 3.6 mg s.c every 4 weeks, only for pre and peri-menopausal patients) and Placebo
or
- Combination Fulvestrant 500 mg i.m every 4 weeks (+ Goserelin 3.6 mg s.c every 4 weeks, only for pre and peri-menopausal patients) and Palbociclib 125 mg per os daily, 3 weeks on and 1 week off.
Patients with documented progressive disease will be considered at the discretion of the investigator for surgery or neoadjuvant chemotherapy. The preferred chemotherapy protocol will be FEC 100 -Taxotere (5fluorouracil 500mg/m2, Epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2 (FEC) q3 weeks for 3 cycles followed by Docetaxel 100 mg/m2 (T) q 3 weeks for 3 cycles) for a total of 6 cycles with clinical and radiological assessment after each 3 cycles of chemotherapy (CT). Chemotherapy candidates will as well undergo surgery. The expected interval between the cycles will be 21 days, unless the patient has not recovered from toxicity. Specific dose adjustments will be set out in the protocol.
Breast and nodal surgery will be performed at completion of therapy (8 months of hormonal therapy for responding patients and 6 additional cycles of CT for non-responders). The type of surgery will be left at the discretion of the investigators.
Radiation therapy and adjuvant systemic treatment and endocrine therapy will be as well left at the discretion of the investigators.
Patients will be followed every 6 months during 5 years post surgery.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Algiers, Algeria
- Center Pierre et Marie Curie
-
Blida, Algeria
- Cancer Center - Blida
-
Oran, Algeria
- CHU - Oran
-
-
-
-
-
Alexandria, Egypt
- University of Alexandria
-
Cairo, Egypt
- National Cancer Institut (NCI)
-
-
-
-
-
Amán, Jordan
- King Hussein Cancer Center (KHCC) - Amman
-
-
-
-
-
Beyrouth, Lebanon
- Hotel Dieu de France
-
-
-
-
-
Casablanca, Morocco
- Hopital Cheikh Khalifa Ibn Zaid
-
Rabat, Morocco
- Department of Oncology - Institut National d'Oncologie
-
-
-
-
-
Riyadh, Saudi Arabia
- King Abdul Aziz Medical City-National Guard Health Affairs (NGHA)
-
Riyadh, Saudi Arabia
- Oncology Center- King Fahad Medical City (KFMC)
-
Riyadh, Saudi Arabia
- Oncology Center- King Saud University Medical City (KSUMC)
-
-
-
-
-
Tunis, Tunisia
- Oncologie Medicale de l'Ariana (SOMA)
-
-
-
-
-
Al Ain, United Arab Emirates
- Tawam Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent prior to beginning specific protocol procedures including expected cooperation of the patients for the treatment and follow-up must be obtained and documented according to the local regulatory requirements.
- Age >18.
- Postmenopausal women or pre-menopausal (with medical or surgical oophorectomy)
- Performance status < 2 (according to WHO criteria).
Histologically confirmed non-metastatic breast cancer (Luminal A or B)
- HR (hormone receptor ) positive (Estrogen or Progesterone)> 1%.
- Her-2 negative (score 0 or 1 by immunochemistry), FISH (fluorescence in situ hybridization) negative if IHC (immuno-histochemistry) score 2).
- Clinical stage II and IIIa.
- No previous breast cancer treatment by surgery, radiotherapy, hormone therapy or chemotherapy.
- Measurable or evaluable disease.
Hematology:
- Neutrophil count ≥ 1.5 G/L.
- Platelet count ≥ 100 G/L.
- Leucocyte count > 3.0 G/L.
- Hb> 9g/dl.
Hepatic function:
- Total bilirubin ≤ 1.5 time the Upper Normal Limit (UNL).
- ASAT (alanine aminotransferase aspartate transaminase ) ≤ 2.5xUNL.
- ALAT (alanine aminotransferase) ≤ 2.5xUNL.
- Alkaline phosphatase ≤ 2.5 time the upper normal limit (UNL).
Renal function:
- Serum creatinine ≤1.5xUNL (and if Serum creatinine >1.5xUNL, creatinine clearance ≥50 mL/min).
- Creatinine clearance ≥40 mL/min in case of MRI.
Metabolic function:
- Serum magnesium ≥ lower limit of normal.
- Serum calcium ≥ lower limit of normal.
- No progressive heart disease and no anthracycline contraindication (normal LVEF ( left ventricular ejection fraction) according to the institution guidelines).
- Negative pregnancy test (urine or serum) within 7 days prior to registration for all women of childbearing potential. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment.
Exclusion Criteria:
- Male patients.
- Her-2 positive tumors or unknown HR/Her-2 status.
- Pregnancy or breast-feeding, or plan to become pregnant within 6 months post treatment.
- No willingness to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months post treatment.
- Any form of breast cancer other than those described in the inclusion criteria, particularly inflammatory and/or overlooked forms (stages IIIb or IV).
- Non-measurable tumour.
- Bilateral breast cancer.
- Previous treatment for breast cancer including surgery for their disease or have had primary axillary dissection, radiotherapy and systemic therapy.
- Patient with history of other cancer, except in situ cervical cancer or baso-cellular skin cancer, considered cured.
- Patient has another disease, which is deemed incompatible with the inclusion in the protocol.
Heart, kidney, medullary, respiratory or liver failure. Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment in the study.
- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease at baseline
- Acute urinary infection, ongoing hemorrhagic cystitis.
- Uncontrolled diabetes.
- Symptomatic or progressive disorder of the central nervous system (CNS) Peripheral neuropathy > grade 2
- Significant psychiatric abnormalities.
- History of hypersensitivity to studied treatment or excipients
- Known previous or ongoing abuse narcotic drug, other medication or alcohol
- Any investigational agent within 30 days before initiation of study treatment.
- No major surgical procedure within 28 days of initiation of treatment.
- Subject unwilling or unable to comply with study requirement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Fulvestrant 500mg + Palbociclib 125mg
+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
|
All patients in all arms will receive Fulvestrant 500mg
Dose reduction to 100 mg and 75 mg
Only for pre or peri menopausal patient
|
Placebo Comparator: Fulvestrant 500mg + Placebos
+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
|
Placebo
All patients in all arms will receive Fulvestrant 500mg
Only for pre or peri menopausal patient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pCR according to Le Chevalier's classification
Time Frame: up to 5 years after the end of treatment period
|
pathological complete response will be assessed according to Le Chevalier's classification between two arms
|
up to 5 years after the end of treatment period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pCR according to Sataloff's classification
Time Frame: up to 5 years after the end of treatment period
|
pathological complete response will be assessed according to Sataloff's classification between two arms
|
up to 5 years after the end of treatment period
|
radiological response
Time Frame: up to 5 years after the end of treatment period
|
radiological response according to the WHO criteria (US/Mammography/MRI)
|
up to 5 years after the end of treatment period
|
Rate of breast conservative surgery
Time Frame: up to 5 years after the end of treatment period
|
Rate of breast conservative surgery will be assessed and compared between two arms
|
up to 5 years after the end of treatment period
|
Safety /Tolerability of the combination Fulvestrant + Palbociclib
Time Frame: up to 5 years after the end of treatment period
|
Safety and tolerability will be assessed in terms of adverse events (AEs), laboratory data and vital signs.
Treatment-related adverse events will be assessed by using CTCAE v4.1 classification
|
up to 5 years after the end of treatment period
|
DFS and OS
Time Frame: up to 5 years after the end of treatment period
|
Evaluation and comparison of Disease Free Survival (DFS) and Overall Survival (OS) between two arms
|
up to 5 years after the end of treatment period
|
Collaborators and Investigators
Investigators
- Study Chair: Jean-Marc Nabholtz, MD, International Cancer Research Group
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Hormone Antagonists
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Fulvestrant
- Palbociclib
- Goserelin
Other Study ID Numbers
- ICRG1201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasm Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Clinical Research Centre, MalaysiaMinistry of Health, Malaysia; National University of Malaysia; Institute for...Not yet recruitingBreast Neoplasm FemaleMalaysia
-
Peking University Cancer Hospital & InstituteRecruiting
-
Peking University Cancer Hospital & InstituteNot yet recruiting
-
University of Rome Tor VergataRecruiting
-
Mario Negri Institute for Pharmacological ResearchRecruiting
-
Peter MacCallum Cancer Centre, AustraliaRecruitingBreast Neoplasm FemaleAustralia
-
Tongji HospitalThe First Affiliated Hospital with Nanjing Medical University; Qilu Hospital... and other collaboratorsNot yet recruitingBreast Neoplasm Female
-
University of CopenhagenUniversity of Southern DenmarkCompleted
-
Mackay Medical CollegeTaipei Veterans General Hospital, TaiwanCompletedBreast Neoplasm Female
Clinical Trials on Placebos
-
Yiling Pharmaceutical Inc.Completed
-
Nova Scotia Health AuthorityRecruiting
-
Beth Israel Deaconess Medical CenterTerminated
-
Intra-Cellular Therapies, Inc.CompletedBipolar Depression | Major Depressive DisorderUnited States, Bulgaria, Russian Federation, Serbia, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unknown
-
GE HealthcareSyneos HealthTerminatedChronic Kidney DiseasesUnited States, Spain, Belgium, Canada, Poland, United Kingdom
-
Viela BioCTI Clinical Trial and Consulting ServicesTerminated
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Viking Therapeutics, Inc.Active, not recruitingNASH - Nonalcoholic SteatohepatitisUnited States, Belgium, France, Mexico, Puerto Rico
-
Shengjing HospitalEnrolling by invitation